Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity

Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasingde novosynthesis of long-chain ceramides

(2013) Resat Cinar et al.   HEPATOLOGY

CB1 antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs

(2012) Stella P. Kim et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance

(2012) Joseph Tam et al.   Cell Metabolism

Blockade of Cannabinoid Receptor 1 Improves Insulin Resistance, Lipid Metabolism, and Diabetic Nephropathy in db/db Mice

(2012) D. H. Nam et al.   ENDOCRINOLOGY

Hepatic Cannabinoid Receptor-1 Mediates Diet-Induced Insulin Resistance via Inhibition of Insulin Signaling and Clearance in Mice

(2012) Jie Liu et al.   GASTROENTEROLOGY

Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity

(2012) Q Ge et al.   INTERNATIONAL JOURNAL OF OBESITY

CB1 blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans

(2012) R Bergholm et al.   INTERNATIONAL JOURNAL OF OBESITY

Activation of Cannabinoid Receptor Type 1 (Cb1r) Disrupts Hepatic Insulin Receptor Signaling via Cyclic AMP-response Element-binding Protein H (Crebh)-mediated Induction ofLipin1Gene

(2012) Dipanjan Chanda et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Suppression of CB1 Cannabinoid Receptor by Lentivirus Mediated Small Interfering RNA Ameliorates Hepatic Fibrosis in Rats

(2012) Si-Wen Chen et al.   PLoS One

Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis

(2011) Jeffrey A. Handy et al.   BIOCHEMICAL JOURNAL

The case for peripheral CB1receptor blockade in the treatment of visceral obesity and its cardiometabolic complications

(2011) George Kunos et al.   BRITISH JOURNAL OF PHARMACOLOGY

Central Endocannabinoid Signaling Regulates Hepatic Glucose Production and Systemic Lipolysis

(2011) J. D. O'Hare et al.   DIABETES

Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice

(2011) D. Song et al.   DIABETOLOGIA

Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: Evidence from cultured explants

(2011) Tony Jourdan et al.   HEPATOLOGY

Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study

(2011) A. S. Wierzbicki et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice

(2011) K S Bell-Anderson et al.   INTERNATIONAL JOURNAL OF OBESITY

Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl4-induced advanced cirrhosis

(2011) Ferdinando A Giannone et al.   LABORATORY INVESTIGATION

Insulin- and leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db mice

(2010) Fengxia Ge et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Significance of serum adiponectin levels in patients with chronic liver disease

(2010) Maria Luisa Balmer et al.   CLINICAL SCIENCE

 -Cell Failure in Diet-Induced Obese Mice Stratified According to Body Weight Gain: Secretory Dysfunction and Altered Islet Lipid Metabolism Without Steatosis or Reduced  -Cell Mass

(2010) M.-L. Peyot et al.   DIABETES

CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice

(2010) T. Jourdan et al.   DIABETES

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

(2010) Joseph Tam et al.   JOURNAL OF CLINICAL INVESTIGATION

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

(2010) Eric J Topol et al.   LANCET

High Fat Diet Induced Hepatic Steatosis Establishes a Permissive Microenvironment for Colorectal Metastases and Promotes Primary Dysplasia in a Murine Model

(2009) Michael Nathan VanSaun et al.   AMERICAN JOURNAL OF PATHOLOGY

Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet

(2009) Mélissa Flamment et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice

(2009) Stéphanie Migrenne et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control

(2009) M-H Son et al.   INTERNATIONAL JOURNAL OF OBESITY

Low Serum Adiponectin Levels Are Predictive of Advanced Hepatic Fibrosis in Patients With NAFLD

(2009) Savvoula Savvidou et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis

(2009) Takeharu Asano et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Prevention of Hepatic Fibrosis in a Murine Model of Metabolic Syndrome with Nonalcoholic Steatohepatitis

(2008) Laurie D. DeLeve et al.   AMERICAN JOURNAL OF PATHOLOGY

Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat

(2008) Jean-Pierre Després et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes

(2008) J. Rosenstock et al.   DIABETES CARE

Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program

(2008) L. Van Gaal et al.   DIABETES CARE

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †

(2008) Luc F. Van Gaal et al.   EUROPEAN HEART JOURNAL

Rimonabant Ameliorates Insulin Resistance via both Adiponectin-dependent and Adiponectin-independent Pathways

(2008) Taku Watanabe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents

(2007) Lauren P. Shearman et al.   EUROPEAN JOURNAL OF PHARMACOLOGY